DOCSLIB.ORG

Worldreginfo - 16A54b73-D5e8-45F7-B39b-04548Fb81703 1984

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Worldreginfo - 16A54b73-D5e8-45F7-B39b-04548Fb81703 1984 WorldReginfo - 16a54b73-d5e8-45f7-b39b-04548fb81703 1984 2019 2019 MARKED DANAHER’S 35TH ANNIVERSARY To honor this milestone, the front cover of this year's annual report features the original Danaher logo and bright blue color palette. We proudly celebrate our company's history as the prelude to a 35 future filled with opportunity. WorldReginfo - 16a54b73-d5e8-45f7-b39b-04548fb81703 By living our core values of building the best team, continuously improving, “ listening to our customers every day and driving innovation, we ultimately deliver long-term shareholder value.” Thomas P. Joyce, Jr. Financial Operating Highlights (dollars in millions except per share data and number of associates) 2019 2018 Sales $ 17,911.1 $ 17,048.5 Operating Profit $ 3,269.4 $ 3,055.1 Net Earnings $ 2,432.3 $ 2,406.3 Net Earnings Per Share (diluted) $ 3.26 $ 3.39 Operating Cash Flow $ 3,657.4 $ 3,644.0 Investing Cash Flow $ (1,166.1) $ (2,873.9) Financing Cash Flow $ 16,589.9 $ (797.4) Capital Expenditures $ (635.5) $ (583.5) Capital Disposals $ 12.8 $ 6.3 Free Cash Flow (Operating Cash Flow less Capital Expenditures plus Capital Disposals) $ 3,034.7 $ 3,066.8 Number of Associates 60,000 58,000 Total Assets* $ 62,081.6 $ 47,832.5 Total Debt ** $ 21,729.1 $ 9,740.3 Stockholders’ Equity $ 30,281.9 $ 28,226.7 Total Capitalization (Total Debt plus Stockholders’ Equity) $ 52,011.0 $ 37,967.0 * 2018 data includes both continuing and discontinued operations ** Long-Term Debt ($21,516.7 for 2019 and $9,688.5 for 2018) plus Notes Payable and Current Portion of Long-Term Debt ($212.4 for 2019 and $51.8 for 2018) All financial data set forth in this annual report relates solely to continuing operations unless otherwise indicated. WorldReginfo - 16a54b73-d5e8-45f7-b39b-04548fb81703 2019 Segment Revenue and Results LIFE SCIENCES • 63% Recurring • 37% Nonrecurring $ 27% MIX GEO 38% North America Adjusted • 7.0 B 27% Western Europe EBITDA Margin • • 27% High-Growth Markets • 8% Other Developed Markets DIAGNOSTICS • 84% Recurring • 16% Nonrecurring $ 26% MIX GEO 39% North America Adjusted • 6.6B 17% Western Europe EBITDA Margin • • 38% High-Growth Markets • 6% Other Developed Markets ENVIRONMENTAL & APPLIED SOLUTIONS • 54% Recurring • 46% Nonrecurring $ 26% MIX GEO 43% North America Adjusted • 4.4B 24% Western Europe EBITDA Margin • • 30% High-Growth Markets • 3% Other Developed Markets All pie charts represent total 2019 revenue. WorldReginfo - 16a54b73-d5e8-45f7-b39b-04548fb81703 Dear Shareholders, THOMAS P. JOYCE, JR. President and Chief Executive Officer WorldReginfo - 16a54b73-d5e8-45f7-b39b-04548fb81703 2019 marked an important milestone in Danaher’s history as we celebrated our thirty-fifth anniversary as a company. Over the course of that time we have continuously evolved toward a better, stronger Danaher—and 2019 was no exception. Our strong financial performance in combination with two significant portfolio moves further advanced our transformation into a higher growth, 2019 Results innovation-driven science & technology company. Our 60,000 associates around the world came together • Core revenue growth of 6.0%, with to deliver our second consecutive year of 6% core Life Sciences and Diagnostics both revenue growth or better, led by high-single digit core achieving 7.0%. revenue growth in both our Life Sciences and Diagnostics segments. Our strong performance was broad-based— • Gross profit margin of 56%. driven by both recently acquired and more tenured • Core operating profit margin businesses in the portfolio—and we believe we continued expansion of 100bps. to capture market share through new product innovation and enhanced commercial execution. • Adjusted diluted net earnings per share (EPS) growth of 9.0%. We achieved 100 basis points of core operating profit • Free cash flow of $3 billion marks margin expansion (core OMX) in 2019, and averaged the 28th consecutive year in which 100 basis points of annual core OMX over the last three our free cash flow has exceeded years. This performance enabled us to continue investing net income. in commercial and innovation initiatives which have contributed to our market share gains. But the numbers only tell part of Danaher’s story in * The acquisition remains subject to customary 2019. This was another pivotal year as we initiated two conditions and is expected to be completed in the first quarter of 2020. important transactions to further our evolution into a higher growth, innovation-driven company. We completed the IPO and split-off of our Dental business into an independent, publicly traded company, Envista (NYSE: NVST). And we announced our agreement to acquire GE’s Biopharma business, which will be called Cytiva* when it officially becomes part of Danaher. Cytiva is an outstanding business with a team of passionate, highly engaged associates whose innovative solutions speed the development and production of revolutionary biopharmaceutical drugs. We believe that together we can generate even greater long-term value for customers, associates and shareholders, and we look forward to welcoming Cytiva to Danaher in 2020. WorldReginfo - 16a54b73-d5e8-45f7-b39b-04548fb81703 The Danaher Another important step toward building The Best Business System Team was the addition of two new members to While our portfolio continues to evolve, the our Board of Directors: Dr. Jessica Mega and Dr. Danaher Business System (DBS) remains the Pardis Sabeti. Both of these women bring diverse driving force in our pursuit of a better, stronger scientific expertise and inspiring perspectives to Danaher. DBS is our core—it’s who we are, and how Danaher, and we are privileged to benefit from we do what we do. The team’s daily commitment their valuable insights. to DBS and our Core Values is what differentiates us. And what unifies us is our Shared Purpose— Customers Talk, Helping Realize Life’s Potential—for our associates, We Listen and Innovation our customers and partners, our communities and Defines Our Future ultimately our shareholders. DBS is our competitive advantage and continued to be the primary driver Our potential is inherently linked to that of our of our strong performance in 2019. customers. An important part of our competitive advantage is the innovative expertise that we Let’s take a closer look at how we lived each of our bring to bear on our customers’ most pressing Core Values this year. challenges addressing global health and safety. Together, we are agents of possibility—partnering The Best Team Wins every day to make a difference in the world. The best team is one that fully reflects who we are At Trojan Technologies, we bring more than and who we want to be. Our people are our greatest forty years of experience with ultra-violet (UV) asset, and realizing their full potential requires that water disinfection to provide our customers we build and sustain a culture of inclusion and with an effective, chemical-free water treatment belonging, where everyone feels empowered to solution. Each day, more than one billion people show up to work each day as their authentic self. Our around the world enjoy clean water that has been efforts around diversity and inclusion are among the treated by Trojan UV systems. And continuous important drivers of associate engagement, and we advancements in our technology now enable our have made good progress on these fronts: over the customers to consume up to 30% less energy last five years, our associate engagement score is up using the UV disinfection process. more than 2,000 basis points. Sepsis affects 30 million people worldwide and We continue to focus on talent development, has a mortality rate higher than prostate cancer, investing in our associates’ potential as long-term breast cancer and HIV/AIDS combined. It is critical Danaher leaders. Our Associate Resource Groups to act quickly with sepsis, but it is very challenging (ARGs) create opportunities for underrepresented to diagnose. Beckman Coulter Diagnostics’ Early individuals including women and people of color to Sepsis Indicator (ESId) is a first-in-class FDA- connect personally and collaborate professionally— cleared hematology parameter that can provide all in the spirit of achieving their highest potential. clinicians with an earlier alert to this life-threatening And we are honored to have been named to Forbes' condition—a significant advancement in the global list of Best Employers for Women (2019) and Best effort to curb this deadly illness. Employers for Diversity (2018 & 2019). WorldReginfo - 16a54b73-d5e8-45f7-b39b-04548fb81703 Another important development in 2019 was Pall’s contribution to a breakthrough pediatric gene therapy, Zolgensma®, which is manufactured using Pall's iCELLis bioreactor. Zolgensma® is the first gene therapy to treat children under the age of two who suffer from spinal muscular atrophy—the number one genetic cause of death for infants. Pall Danaher Core Values is proud to contribute to a life-changing treatment for this devastating disease. Finally, at Videojet, we are using digital technology to help customers run their packaging processes and plants more efficiently, with fewer instances of disruptive and costly downtime. Videojet’s industry-leading installed base of more than 10,000 connected printers enables service teams to resolve 50% of customer problems remotely today. The data generated provides valuable insights to help Videojet design better new products for customers—eliminating issues that were encountered in the past and, in turn, enhancing productivity. Kaizen is Our Way of Life At the heart of DBS is kaizen, “continuous improvement.” We challenge ourselves to be better every day, and the tools and processes of DBS are uniquely impactful in this endeavor. Our world-leading water quality analytics business, Hach, continues to demonstrate the power of DBS twenty years into its journey as part of Danaher. Driven by a commitment to disciplined execution and a foundation of continuous improvement, Hach has evolved from a $130 million annual revenue business when it was acquired in 1999 to $1.5 billion today and the cornerstone of our Water Quality platform.
Load more

Recommended publications
  • 2019 Annual Report
    1984 2019 2019 MARKED DANAHER’S 35TH ANNIVERSARY To honor this milestone, the front cover of this year's annual report features the original Danaher logo and bright blue color palette. We proudly celebrate our company's history as the prelude to a 35 future filled with opportunity. By living our core values of building the best team, continuously improving, “ listening to our customers every day and driving innovation, we ultimately deliver long-term shareholder value.” Thomas P. Joyce, Jr. Financial Operating Highlights (dollars in millions except per share data and number of associates) 2019 2018 Sales $ 17,911.1 $ 17,048.5 Operating Profit $ 3,269.4 $ 3,055.1 Net Earnings $ 2,432.3 $ 2,406.3 Net Earnings Per Share (diluted) $ 3.26 $ 3.39 Operating Cash Flow $ 3,657.4 $ 3,644.0 Investing Cash Flow $ (1,166.1) $ (2,873.9) Financing Cash Flow $ 16,589.9 $ (797.4) Capital Expenditures $ (635.5) $ (583.5) Capital Disposals $ 12.8 $ 6.3 Free Cash Flow (Operating Cash Flow less Capital Expenditures plus Capital Disposals) $ 3,034.7 $ 3,066.8 Number of Associates 60,000 58,000 Total Assets* $ 62,081.6 $ 47,832.5 Total Debt ** $ 21,729.1 $ 9,740.3 Stockholders’ Equity $ 30,281.9 $ 28,226.7 Total Capitalization (Total Debt plus Stockholders’ Equity) $ 52,011.0 $ 37,967.0 * 2018 data includes both continuing and discontinued operations ** Long-Term Debt ($21,516.7 for 2019 and $9,688.5 for 2018) plus Notes Payable and Current Portion of Long-Term Debt ($212.4 for 2019 and $51.8 for 2018) All financial data set forth in this annual report relates solely to continuing operations unless otherwise indicated.
    [Show full text]
  • 2017 INVESTOR & ANALYST DAY December 14, 2017
    2017 INVESTOR & ANALYST DAY December 14, 2017 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, deterioration of or instability in the economy, the markets we serve and the financial markets, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify, consummate and integrate appropriate acquisitions and successfully complete divestitures and other dispositions, our ability to integrate the recent acquisitions of Pall Corporation and Cepheid and achieve the anticipated benefits of such transactions, contingent
    [Show full text]
  • Journal 2428
    Iris um Oifig Maoine Intleachtúla na hÉireann Journal of the Intellectual Property Office of Ireland Iml. 96 Cill Chainnigh 06 January 2021 Uimh. 2428 CLÁR INNSTE Cuid I Cuid II Paitinní Trádmharcanna Leath Leath Official Notice 1 Official Notice 1 Applications for Patents 3 Applications for Trade Marks 3 Patents Granted 4 Oppositions under Section 43 68 European Patents Granted 5 Application(s) Withdrawn 68 Applications Withdrawn, Deemed Withdrawn or Trade Marks Registered 69 Refused 151 Trade Marks Renewed 69 Request for Grant of Supplementary Protection Application(s) for Leave to Alter Registered Certificate 167 Trade Mark(s) 71 Supplementary Protection Certificate Withdrawn 168 Leave to Alter Registered Trade Mark(s) Supplementary Protection Certificate Rejected 168 Granted 71 Application for Extension of the Duration of a International Registrations under the Madrid Supplementary Protection Certificate 169 Protocol 72 Errata 170 International Trade Marks Protected 93 Cancellations effected for the following goods/services under the Madrid protocol 95 Dearachtaí Designs Information under the 2001 Act Designs Registered 171 The Journal of the Intellectual Property Office of Ireland is published fortnightly. Each issue is freely available to view or download from our website at www.ipoi.gov.ie © Rialtas na hÉireann, 2021 © Government of Ireland, 2021 1 (06/01/2021) Journal of the Intellectual Property Office of Ireland (No. 2428) Iris um Oifig Maoine Intleachtúla na hÉireann Journal of the Intellectual Property Office of Ireland Cuid I Paitinní agus Dearachtaí No. 2428 Wednesday, 6 January, 2021 NOTE: The office does not guarantee the accuracy of its publications nor undertake any responsibility for errors or omissions or their consequences.
    [Show full text]
  • 2018 Annual Report
    2018 Annual Report Danaher 2018 Annual Report Financial Operating Highlights (dollars in millions except per share data and number of associates) 2018 2017 Sales $ 19,893.0 $ 18,329.7 Operating Profit $ 3,403.8 $ 2,990.4 Net Earnings $ 2,650.9 $ 2,469.8 Net Earnings Per Share (diluted) $ 3.74 $ 3.50 Operating Cash Flow $ 4,022.0 $ 3,477.8 Investing Cash Flow $ (2,949.4) $ (843.4) Financing Cash Flow $ (797.4) $ (3,098.5) Capital Expenditures $ (655.7) $ (619.6) Capital Disposals $ 6.3 $ 32.6 Free Cash Flow (Operating Cash Flow less Capital Expenditures plus Capital Disposals) $ 3,372.6 $ 2,890.8 Number of Associates 71,000 67,000 Total Assets $ 47,832.5 $ 46,648.6 Total Debt * $ 9,740.3 $ 10,522.1 Stockholders’ Equity $ 28,226.7 $ 26,367.8 Total Capitalization (Total Debt plus Stockholders’ Equity) $ 37,967.0 $ 36,889.9 * Long-Term Debt ($9,688.5 for 2018 and $10,327.4 for 2017) plus Notes Payable and Current Portion of Long-Term Debt ($51.8 for 2018 and $194.7 for 2017) All financial data set forth in this annual report relates solely to continuing operations unless otherwise indicated. 2018 Annual Report Dear Shareholders, As I begin my 30th year at Danaher, it is humbling to reflect on what our team has achieved over that time and exciting to think about the opportunities that still lie ahead. Financially and strategically, 2018 was an outstanding year. With the Danaher Business System (DBS) as our driving force, we strengthened our footholds in attractive, fast-growing markets and enhanced our competitive positions.
    [Show full text]
  • EU Top Applicants 2010-2014 Based on Assignees2014 5Yr.Tsv
    EU top applicants 2010-2014 Based on Assignees2014 5yr.tsv table_row ordering_cd 15943 309 13406 105 13407 105 13408 105 13409 105 13410 105 13411 105 13412 105 13413 105 13414 105 13415 105 13416 105 13417 105 13418 105 13419 105 13420 105 13421 105 13422 105 13423 105 13424 105 Page 1 of 1235 09/26/2021 EU top applicants 2010-2014 Based on Assignees2014 5yr.tsv st_country_cd us_or_foreign FRX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) Page 2 of 1235 09/26/2021 EU top applicants 2010-2014 Based on Assignees2014 5yr.tsv state_country_of_origin assignee_name FRANCE IMERJ, LTD. AUSTRIA INFINEON TECHNOLOGIES AG AUSTRIA ~INDIVIDUALLY OWNED PATENT AUSTRIA AMS AG AUSTRIA NXP B.V. AUSTRIA JULIUS BLUM GMBH AUSTRIA BAXTER INTERNATIONAL INC. AUSTRIA EPCOS AG AUSTRIA INFINEON TECHNOLOGIES AUSTRIA AG AUSTRIA MED-EL ELEKTROMEDIZINISCHE GERAETE GMBH AUSTRIA SIEMENS AKTIENGESELLSCHAFT AUSTRIA AVL LIST GMBH AUSTRIA MAGNA POWERTRAIN AG & CO KG AUSTRIA HILTI AKTIENGESELLSCHAFT AUSTRIA BOEHRINGER INGELHEIM INTERNATIONAL GMBH AUSTRIA FRONIUS INTERNATIONAL GMBH AUSTRIA SIEMENS VAI METALS TECHNOLOGIES GMBH AUSTRIA CONTINENTAL AUTOMOTIVE GMBH AUSTRIA INTEL MOBILE COMMUNICATIONS GMBH AUSTRIA MAGNA STEYR FAHRZEUGTECHNIK AG & CO. KG Page 3 of 1235 09/26/2021 EU top applicants 2010-2014 Based on Assignees2014 5yr.tsv CY_2010 CY_2011
    [Show full text]
  • INVESTOR & ANALYST MEETING December 16, 2015
    INVESTOR & ANALYST MEETING December 16, 2015 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future, are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, deterioration of or instability in the economy, the markets we serve and the financial markets, the impact of our restructuring activities on our ability to grow, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new and enhanced products and services and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our ability to successfully identify, consummate and integrate appropriate acquisitions and successfully complete divestitures and other dispositions, our ability to integrate the recently acquired Pall Corporation and achieve the anticipated benefits of that transaction, our ability to successfully consummate the separation of Danaher into two public companies and realize the anticipated benefits of that transaction, contingent liabilities relating to
    [Show full text]
  • INVESTOR & ANALYST MEETING December 15, 2016
    INVESTOR & ANALYST MEETING December 15, 2016 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, deterioration of or instability in the economy, the markets we serve and the financial markets, the impact of our restructuring activities on our ability to grow, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our ability to successfully identify, consummate and integrate appropriate acquisitions and successfully complete divestitures and other dispositions, our ability to integrate the recent acquisitions of Pall Corporation and Cepheid and achieve the anticipated benefits of those transactions, contingent liabilities relating to acquisitions and divestitures (including tax-related and other contingent liabilities relating to the distributions of each of Fortive Corporation
    [Show full text]
  • Exhibit N-2: NYSE and AMEX UTP Issues by Issuer Name (As of 8/9/05) SYMBOL ISSUER NAME ISSUE TYPE MARKET a Agilent Technologies, Inc
    Exhibit N-2: NYSE and AMEX UTP Issues by Issuer Name (as of 8/9/05) SYMBOL ISSUER NAME ISSUE TYPE MARKET A Agilent Technologies, Inc. Common Stock or Equivalent NYSE AA Alcoa Inc. Common Stock or Equivalent NYSE AA.PR Alcoa Inc. Preferred Stock AMEX AAA Asco Plc Ads Common Stock or Equivalent NYSE AAC Ableauctions.Com Inc Common Stock or Equivalent AMEX AAI AirTran Holdings, Inc. Common Stock or Equivalent NYSE AAP Advance Auto Parts Inc Common Stock or Equivalent NYSE ABB ABB Ltd Common Stock or Equivalent NYSE ABC AmerisourceBergen Corporation (Holding Co) Common Stock or Equivalent NYSE ABD.WI Acco Brands Corporation Common Stock or Equivalent NYSE ABG Asbury Automotive Group Inc Common Stock or Equivalent NYSE ABI Applera Corporation Common Stock or Equivalent NYSE ABK Ambac Financial Group, Inc. Common Stock or Equivalent NYSE ABL American Biltrite Inc. Common Stock or Equivalent AMEX ABM ABM Industries Incorporated Common Stock or Equivalent NYSE ABN ABN Amro Holding N.V. Common Stock or Equivalent NYSE ABN.PRE ABN Amro Holding N.V. Other Securities NYSE ABN.PRF ABN Amro Holding N.V. Other Securities NYSE ABN.PRG ABN Amro Holding N.V. Other Securities NYSE ABP Abraxas Petroleum Corporation Common Stock or Equivalent AMEX ABR Arbor Realty Trust Common Stock or Equivalent NYSE ABS Albertson's, Inc. Common Stock or Equivalent NYSE ABT Abbott Laboratories Common Stock or Equivalent NYSE ABV Companhia de Bebidas das Americas - AmBev Common Stock or Equivalent NYSE ABV.C Companhia de Bebidas das Americas - AmBev Common Stock or Equivalent NYSE ABW.PRA Associated Banc-Corp Other Securities NYSE ABX Barrick Gold Corporation Common Stock or Equivalent NYSE ABY Abitibi-Consolidated, Inc.
    [Show full text]
  • 2 0 1 5 a N N U a L R E P O
    2015 ANNUAL REPORT FINANCIAL OPERATING HIGHLIGHTS (Dollars in Millions Except Per Share Data and Number of Associates) 2015 2014 Sales* $ 20,563.1 $ 19,154.0 Operating Profit* $ 3,469.1 $ 3,346.6 Net Earnings * $ 2,598.7 $ 2,543.1 Net Earnings Per Share (diluted) * $ 3.67 $ 3.56 Operating Cash Flow* $ 3,828.0 $ 3,618.0 Capital Expenditures* $ 633.0 $ 580.6 Free Cash Flow $ 3,195.0 $ 3,037.4 (Operating Cash Flow less Capital Expenditures) * Number of Associates 81,000 71,000 Total Assets $ 48,222.2 $ 36,991.7 Total Debt ** $ 12,870.4 $ 3,473.4 Stockholders’ Equity $ 23,764.0 $ 23,449.8 Total Capitalization $ 36,634.4 $ 26,923.2 (Total Debt plus Stockholders’ Equity) * From Continuing Operations ** Long-Term Debt ($12,025.2 for 2015 and $3,401.5 for 2014) plus Notes Payable and Current Portion of Long-Term Debt ($845.2 for 2015 and $71.9 for 2014) Environmental Our products help protect the global water supply, facilitate environmental stewardship, enhance the safety of personal data and improve business efficiencies. Our Water Quality platform provides instrumentation and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, waste, ground and ocean water in residential, commercial, industrial and natural resource applications. Our Gilbarco Veeder-Root platform is a leading worldwide provider of solutions and services focused on fuel dispensing, remote fuel management, point-of-sale and payment systems, environmental compliance, vehicle tracking and fleet management. With a lightweight, compact and rugged design, the Surveyor HL and Hydrolab HL4 from OTT Hydromet, a division of Hach, help environmentalists measure a variety of water quality parameters in real-time, or for continuous unattended monitoring.
    [Show full text]
  • Finding a Way Through M&A
    RESEARCHNovember REPORT18, 2019 FindingNovember a Way through18, 2019 M&A Stock Rating HOLD Price Target CAD $123.58 Current Price CAD $140.49 Bear Price Bull Case Target Case $107.75 $123.58 $139.41 Ticker DHR Danaher Corporation Market Cap (MM) $102,707 Finding a Way through Market Cap/LFCF NTM 33.5x M&A EV/EBITDA NTM 22.5x 52 Week Performance After conducting an analysis of the Medical Devices space at large, the Healthcare Team decided that Danaher Corporation’s ability to 120 effectively use inorganic growth as a competitive advantage warrant a further look. This report outlines various elements of Danaher’s business that we wanted to gain conviction on before reaching a 100 decision on the name. Overall, we believe that Danaher’s highly disciplined M&A strategy that incorporates the Danaher Business System (DBS) and philosophy 80 of detail-oriented accountability has demonstrated a proven ability to select, integrate and grow acquisition targets. Coupled with its current business, we believe that Danaher has strong fundamentals. 60 Despite our conviction in Danaher’s fundamentals, our price target of 27-Feb-17 29-Apr-17 29-Jun-17 $123.58 is much lower than their current price of $140.59. Therefore, DHR S&PS&P 100 Index the Healthcare Team has decided on a stock rating of HOLD. Industrials Laura Wu [email protected] Ruby Harris [email protected] William Cao [email protected] The information in this document is for EDUCATIONAL and NON-COMMERCIAL use only and is not intended to Tina Huang constitute specific legal, accounting, financial or tax advice for any individual.
    [Show full text]
  • Danaher Corporation 2016 Annual Report
    2016 ANNUAL REPORT “ I see our future as a bright one. We have a terrific team of hard-working, dedicated associates around the world. We have exciting new products coming out, providing customers with new and innovative solutions to their daily work.” THOMAS P. JOYCE, JR. President and Chief Executive Officer FINANCIAL OPERATING HIGHLIGHTS (dollars in millions except per share data and number of associates) 2016 2015 Sales $ 16,882.4 $ 14,433.7 Operating Profit $ 2,750.9 $ 2,162.2 Net Earnings $ 2,153.4 $ 1,746.7 Net Earnings Per Share (diluted) $ 3.08 $ 2.47 Operating Cash Flow $ 3,087.5 $ 2,832.2 Capital Expenditures $ 589.6 $ 512.9 Free Cash Flow (Operating Cash Flow less Capital Expenditures) $ 2,497.9 $ 2,319.3 Number of Associates 62,000 59,000 Total Assets* $ 45,295.3 $ 48,222.2 Total Debt ** $ 12,269.0 $ 12,870.4 Stockholders’ Equity $ 23,076.8 $ 23,764.0 Total Capitalization (Total Debt plus Stockholders’ Equity) $ 35,345.8 $ 36,634.4 * Related to both continuing and discontinued operations ** Long-Term Debt ($9,674.2 for 2016 and $12,025.2 for 2015) plus Notes Payable and Current Portion of Long-Term Debt ($2,494.8 for 2016 and $845.2 for 2015) All financial data set forth in this annual report relates solely to continuing operations unless otherwise indicated. Life Sciences Every day, scientists around the world are working to understand the causes of and treatments for chronic diseases and infections at the cellular level. Our Life Sciences businesses make this leading-edge scientific research possible, and our capabilities extend beyond research to power the creation of biopharmaceuticals, cell therapies and more.
    [Show full text]
  • Danaher Corporation Annual Report 2018
    Danaher Corporation Annual Report 2018 Form 10-K (NYSE:DHR) Published: February 21st, 2018 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________ FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-8089 ____________________________________ DANAHER CORPORATION (Exact name of registrant as specified in its charter) Delaware 59-1995548 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification Number) 2200 Pennsylvania Ave. N.W., Suite 800W Washington, D.C. 20037-1701 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: 202-828-0850 Securities Registered Pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange On Which Registered Common Stock $.01 par value New York Stock Exchange €600,000,000 1.000% Senior Notes due 2019 New York Stock Exchange €250,000,000 Floating Rate Senior Notes due 2022 New York Stock Exchange €800,000,000 1.700% Senior Notes due 2022 New York Stock Exchange €800,000,000 2.500% Senior Notes due 2025 New York Stock Exchange €600,000,000 1.200% Senior Notes due 2027 New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: NONE (Title of Class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]